2024
ERS statement on transition of care in childhood interstitial lung diseases
POHUNEK, Petr, Effrosyni MANALI, Susanne VIJVERBERG, Julia CARLENS, Felix CHUA et. al.Základní údaje
Originální název
ERS statement on transition of care in childhood interstitial lung diseases
Autoři
POHUNEK, Petr, Effrosyni MANALI, Susanne VIJVERBERG, Julia CARLENS, Felix CHUA, Ralph EPAUD, Carlee GILBERT, Matthias GRIESE, Bulent KARADAG, Eitan KEREM, Václav KOUCKÝ, Nadia NATHAN, Spyridon PAPIRIS, Suzanne TERHEGGEN-LAGRO, Lukáš PLCH, Alba Torrent VERNETTA a Andrew BUSH
Vydání
EUROPEAN RESPIRATORY JOURNAL, ENGLAND, EUROPEAN RESPIRATORY SOC JOURNALS LTD, 2024, 0903-1936
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 24.300 v roce 2022
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 21. 6. 2024 14:07, Mgr. Lukáš Plch
Anotace
V originále
Interstitial lung diseases (ILD) are a heterogeneous group of rare diffuse diseases affecting the lung parenchyma in children and adults. Childhood interstitial lung diseases (chILD) are often diagnosed at very young age, affect the developing lung, and can have different presentations and prognosis compared to adult forms of these diseases. Also, chILD in many cases may apparently remit, and have a better response to therapy and better prognosis than adult ILD. Many affected children will reach adulthood with minimal activity or clinical remission of the disease. They need continuing care and follow-up from childhood to adulthood if the disease persists and progresses over time but also if they are asymptomatic and in full remission. Therefore, for every chILD patient an active transition process from paediatric to adult care should be guaranteed. This ERS statement provides a review of the literature and current practice concerning transition of care in chILD. It draws on work in existing transition care programs in other chronic respiratory diseases, disease-overarching transition of care programs, evidence on the impact of these programs on clinical outcomes, current evidence regarding long-term remission of chILD as well as the lack of harmonisation between the current adult ILD and chILD classifications impacting on transition of care. While the transition system is well established in several chronic diseases, such as cystic fibrosis or diabetes mellitus, we could not find sufficient published evidence on transition systems in chILD. This statement summarises current knowledge but cannot yet provide evidence-based recommendations for clinical practice.